Stemline Therapeutics, Inc.
1675 York Avenue
Suite 30-E
New York
New York
10128
United States
Tel: 212-831-1111
Website: http://www.stemline.com/
Email: info@stemline.com
139 articles about Stemline Therapeutics, Inc.
-
Stemline Therapeutics, Inc. Announces Presentations of SL-401 Updated Clinical Trial Results in Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and SL-101 Preclinical Efficacy Data Against Hodgkin's Lymphoma at the 54
12/7/2012
-
Stemline Therapeutics, Inc.' Lead Clinical Candidate SL-401 Induces a Complete Response in a Patient with a Drug-Refractory Plasmacytoid Dendritic Cell Neoplasm
11/9/2012
-
Stemline Therapeutics, Inc. Postpones IPO
8/9/2012
-
Stemline Therapeutics, Inc. Announces Two Presentations of Direct Injection Synthetic Peptide Vaccine for Brain Cancer, Now Being Developed as SL-701, at the Annual Meeting of the American Association for Cancer Research (AACR)
4/18/2012
-
Stemline Therapeutics, Inc. Files for $50 Million US IPO
4/3/2012
-
Stemline Therapeutics, Inc. Appoints Kevin Buchi, Former CEO of Cephalon, Inc., to Its Board of Directors
3/15/2012
-
Stemline Therapeutics, Inc. Names Eric K. Rowinsky, M.D. Chief Medical Officer and Head of Research and Development
1/9/2012
-
Stemline Therapeutics, Inc. to Present at the Oppenheimer 22nd Annual Healthcare Conference
12/12/2011
-
Stemline Therapeutics, Inc. Announces Two Poster Presentations of SL-401 Efficacy Data Against Lymphoid Cancers at the 53rd Annual Meeting of the American Society of Hematology (ASH)
12/8/2011
-
Stemline Therapeutics, Inc. Announces Oral Presentation of Positive Phase I/II Trial Results with Novel Brain Cancer Vaccine at the American Society of Clinical Oncology 2011 Annual Meeting
6/6/2011
-
Stemline Therapeutics, Inc. Announces Oral Presentation of Positive Phase I/II Trial Results with Novel Brain Cancer Vaccine at the American Society of Clinical Oncology 2011 Annual Meeting
6/2/2011
-
Stemline Therapeutics, Inc. Receives Orphan Drug Designation for SL-401 for the Treatment of Acute Myeloid Leukemia
3/9/2011
-
Stemline Therapeutics, Inc. Licenses Phase I/II Brain Cancer Vaccine - Shows Promise in Clinical Trial Conducted at University of Pittsburgh
2/23/2011
-
Stemline Therapeutics, Inc. Announces Presentations of SL-401 Clinical and Pre-Clinical Efficacy at the 52nd Annual Meeting of the American Society of Hematology
12/1/2010
-
Stemline Therapeutics, Inc. Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology
12/4/2009
-
Stemline Therapeutics, Inc. Expands Clinical Oncology Program Directed at Cancer Stem Cells With Addition of M. D. Anderson Cancer Center
11/30/2009
-
Stemline Therapeutics, Inc. CEO to Present at IBC Life Sciences's New Frontiers in Cancer Drug Development Conference
7/30/2009
-
Stemline Therapeutics, Inc. Raises $12.5 Million
4/9/2008
-
Stemline Therapeutics, Inc. In-Licenses Phase I Oncology Compound
3/7/2007